Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.
2. Markman M, Liu PY, Wilczynski S, et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003, 21:2460–2465.
3. Browder T, Butterfield CE, Kraling BM, et al.: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000, 60:1878–1886.
4. Epstein RJ: Maintenance therapy to suppress micrometastasis: The new challenge for adjuvant cancer treatment. Clin Cancer Res 2005, 11:5337–5341.
5. Markman M: Viewing ovarian cancer as a "chronic disease": What exactly does this mean? Gynecol Oncol 2006, 100:229–230.